3681 Stock Overview
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases primarily monoclonal antibody (mAb)-based biologics.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
SinoMab BioScience Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.90 |
| 52 Week High | HK$1.99 |
| 52 Week Low | HK$1.03 |
| Beta | 0.78 |
| 1 Month Change | 29.25% |
| 3 Month Change | 19.50% |
| 1 Year Change | 6.74% |
| 3 Year Change | -48.65% |
| 5 Year Change | n/a |
| Change since IPO | -68.33% |
Recent News & Updates
Recent updates
Update: SinoMab BioScience (HKG:3681) Stock Gained 21% In The Last Year
Mar 04
What You Need To Know About SinoMab BioScience Limited's (HKG:3681) Investor Composition
Jan 28Did SinoMab BioScience Limited (HKG:3681) Insiders Buy Up More Shares?
Jan 01
Loss-Making SinoMab BioScience Limited (HKG:3681) Expected To Breakeven In The Medium-Term
Nov 30Shareholder Returns
| 3681 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 2.2% | 3.7% | 2.3% |
| 1Y | 6.7% | -41.4% | -10.9% |
Return vs Industry: 3681 exceeded the Hong Kong Biotechs industry which returned -41.4% over the past year.
Return vs Market: 3681 exceeded the Hong Kong Market which returned -10.9% over the past year.
Price Volatility
| 3681 volatility | |
|---|---|
| 3681 Average Weekly Movement | 7.0% |
| Biotechs Industry Average Movement | 9.4% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in HK Market | 14.5% |
| 10% least volatile stocks in HK Market | 3.7% |
Stable Share Price: 3681's share price has been volatile over the past 3 months.
Volatility Over Time: 3681's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 233 | Shawn Leung | www.sinomab.com |
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases primarily monoclonal antibody (mAb)-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren’s syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a Bruton’s tyrosine kinase inhibitor, which is in Phase II clinical trial for the treatment of pemphigus, as well as in phase 1 clinical trial to treat multiple sclerosis, SLE, and NMOSD.
SinoMab BioScience Limited Fundamentals Summary
| 3681 fundamental statistics | |
|---|---|
| Market cap | HK$2.07b |
| Earnings (TTM) | -HK$262.79m |
| Revenue (TTM) | HK$4.75m |
436.9x
P/S Ratio-7.9x
P/E RatioIs 3681 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3681 income statement (TTM) | |
|---|---|
| Revenue | CN¥4.39m |
| Cost of Revenue | CN¥943.00k |
| Gross Profit | CN¥3.45m |
| Other Expenses | CN¥246.56m |
| Earnings | -CN¥243.11m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.22 |
| Gross Margin | 78.53% |
| Net Profit Margin | -5,535.31% |
| Debt/Equity Ratio | 132.4% |
How did 3681 perform over the long term?
See historical performance and comparison